Net Cash Provided by (Used in) Investing Activities of Entrada Therapeutics, Inc. from 31 Dec 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Summary
Entrada Therapeutics, Inc. annual and quarterly Net Cash Provided by (Used in) Investing Activities in USD history and change rate from 31 Dec 2020 to 31 Dec 2025.
  • Entrada Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities for the quarter ending 31 Mar 2025 was $4,783,000, a 82% decline year-over-year.
  • Entrada Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2025 was $116,808,000.
  • Entrada Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2024 was $27,798,000, a 80% increase from 2023.
  • Entrada Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2023 was $138,395,000, a 6.9% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Investing Activities, Annual (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Investing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Quarterly Change (%)

Entrada Therapeutics, Inc. Annual Net Cash Provided by (Used in) Investing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $116,808,000 +$144,606,000 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $27,798,000 +$110,597,000 +80% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $138,395,000 +$10,255,000 +6.9% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $148,650,000 -$144,070,000 -3146% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
2021 $4,580,000 -$2,262,000 -98% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
2020 $2,318,000 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY

Entrada Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Investing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $4,783,000 -$21,364,000 -82% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q1 2024 $26,147,000 +$66,591,000 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q1 2023 $40,444,000 +$141,089,000 +78% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q1 2022 $181,533,000 -$180,625,000 -19893% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q1 2021 $908,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.